Mass General Cancer Center, a founding member of the Mass General Brigham system, has received the largest gift in its 34-year history from philanthropists Jason and Keely Krantz to power the future of cancer research. In honor of their landmark contribution, the Cancer Center’s pre-eminent research division will now be known as the Krantz Family Center for Cancer Research. The…
Read More
A new study by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests a common brain network exists among people with substance use disorder. By evaluating data from across more than 144 studies of addiction, the team found abnormalities across substance use disorders mapped to a common brain network across substances and…
Read More
Laminar Pharma announces that the U.S. Food & Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to LAM561 (idroxioleic acid, sodium) an investigational drug candidate for patients with Pediatric-Type Diffuse High Grade Glioma (pdHGG). “Pediatric patients who develop Pediatric-Type Diffuse High Grade Glioma face a significant unmet need with limited treatment options, presenting differential characteristics from adult patients…
Read More
High up in the mountains of Kenya are the lush Taita Hills — a vibrant and beautiful rainforest that seems entirely detached from the dry savannah common in the rest of the country. It is roughly halfway between the two largest cities of Nairobi and Mombasa, taking hours to reach by train and car. It’s also swarming with bats. Those…
Read More
Sylvia Abente, a clinical neurologist at the Universidad Nacional de Asunción in Paraguay, investigates the range of symptoms that characterize epilepsy. She works with indigenous peoples in Paraguay, and her fluency in Spanish and Guarni—the two official languages of Paraguay—allows her to help patients find the words to describe their epilepsy symptoms so she can treat them. Juan Carlos Caicedo…
Read More
Slowey McManus Communications (SMC) announced the launch of the Communications Accelerator program for emerging life sciences companies. The program gives young, growing life science companies a concentrated group of services to prepare them to come out of stealth or semi-stealth mode and introduce themselves to the public, with an emphasis on reaching target audiences: investors, partners, and scientific talent. Many…
Read More
A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma (ccRCC), a form of kidney cancer, using image processing with deep learning. Their AI-based assessment tool evaluates two-dimensional pictures of a tumor sample on a pathology slide and identifies previously underappreciated features, such as tumor microheterogeneity, that could…
Read More
Team COMBAT (Conquering Cancer in Obesity through Metabolism, Behaviour And Therapy) have been selected as finalists for CRUK Grand Cancer Challenge. The team is led by Dr Lydia Lynch , alongside Dr Marcia Haigis and Dr Arlene Sharpe. Team COMBAT aims to explore obesity-related cancer risk and mechanisms to reduce this risk through the metabolic lens. Team COMBAT is competing…
Read More
Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with polycythemia vera (PV). “We are delighted to have received Fast Track designation…
Read More